Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Triple-negative breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes. Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients. 17-Demethoxy-reblastatin (17-DR), a novel nonbenzoquinone- type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity. In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated. These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells. Down-regulation of the key Hsp90-dependent tumor-driving molecules, such as RIP1 and MMP-9, by 17-DR may be related to these effects. Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.
Abstract
Triple-negative breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes. Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients. 17-Demethoxy-reblastatin (17-DR), a novel nonbenzoquinone- type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity. In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated. These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells. Down-regulation of the key Hsp90-dependent tumor-driving molecules, such as RIP1 and MMP-9, by 17-DR may be related to these effects. Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.
참고문헌 (28)
- Amend K, "Breast cancer in African-American women: differences in tumor biology from European-American women", Cancer Res, 66, pp.8327~8330 (2006)
- Baichwal VR, "Activate NF-κB or die?", Curr. Biol, 7, pp.94~96 (1997)
- Bryan BB, "Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer", Mod. Pathol, 19, pp.617~621 (2006)
- Cheng Q, "Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer", Breast Cancer Res, 14, pp.62~ (2012)
- Chiosis G, "Hsp90: the vulnerable chaperone", Drug Discov. Today, 9, pp.881~888 (2004)
- Da Silva VC, "The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics", J. Proteomics, 75, pp.2790~2802 (2012)
- Groblewska M, "The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer", Folia Histochem. Cytobiol, 50, pp.12~19 (2012)
- Han HZ., "Research in progress of triple negative breast cancer molecular targeted therapy", Chinese Clin. Oncol, 17, pp.470~474 (2012)
- Heath EI, "A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer", Clin. Cancer Res, 14, pp.7940~7946 (2008)
- Hong YS, "Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin", J. Am. Chem. Soc, 126, pp.11142~11143 (2004)
- Kamal A, "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors", Nature, 69, pp.5898~5903 (2003)
- Kim MS, "17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion", Mol. Cancer Res, 6, pp.1657~1665 (2008)
- Kim W, "Rational biosynthetic engineering for optimization of geldanamycin analogues", Chembiochem, 10, pp.1243~1251 (2009)
- Kim W, "Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring", Chembiochem, 8, pp.1491~1494 (2007)
- Messaoudi S, "Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010", Expert Opin. Ther. Pat, 21, pp.1501~1542 (2010)
- Mosmann T, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays", J. Immunol. Methods, 65, pp.55~63 (1983)
- Mosser DD, "Molecular chaperones and the stress of oncogenesis", Oncogene, 23, pp.2907~2918 (2004)
- Sankhala KK, "Heat shock proteins: a potential anticancer target", Curr. Drug Targets, 12, pp.2001~2008 (2011)
- Shin, Jin Chul, "Characterization of Tailoring Genes Involved in the Modification ofGeldanamycin Polyketide in Streptomyces hygroscopicus JCM4427", Journal of Microbiology and Biotechnology, 18(6), pp.1101~1108 (2008), 한국미생물·생명공학회
- Whitesell L, "Hsp90 and the chaperoning of cancer", Nat. Rev. Cancer, 5, pp.761~772 (2005)
- Whitesell L, "Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation", Proc. Natl. Acad. Sci. USA, 91, pp.8324~8328 (1994)
- Cheng-Zhu Wu, "New Geldanamycin Analogs from Streptomyces hygroscopicus", Journal of Microbiology and Biotechnology, 22(11), pp.1478~1481 (2012), 한국미생물·생명공학회[DOI]
- Wu CZ, "Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase", Appl. Environ. Microbiol, 78, pp.7680~7686 (2012)
- Wrona IE, "Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90", J. Org. Chem, 75, pp.2820~2835 (2010)
- Wu ZS, "Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer", Int. J. Cancer, 122, pp.2050~2056 (2008)
- Xing H, "Activation of fibronectin", PI3K, Cancer Lett, pp.2008, 261[DOI]
- Zhang H, "Targeting multiple signal transduction pathways through inhibition of Hsp90", J. Mol. Med, 82, pp.488~499 (2004)
- Zhao S, "High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC)patients", Med. Oncol, 30, pp.335~ (2013)